Efficacy of empagliflozin in patients with heart failure across kidney risk categories
Butler J, Packer M, Siddiqi TJ, et al.
J Am Coll Cardiol. 2023;81(19):1902–1914.
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Butler J, Packer M, Siddiqi TJ, et al.
J Am Coll Cardiol. 2023;81(19):1902–1914.
Leggi
Philis-Tsimikas A, Asong M, Franek E, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00093-1.
Leggi
Pei Y, Shu Y, Deng B , Liu Y
BMC Endocr Disord. 2023;23(1):98.
Leggi
Zhang Y, Liu L, Wei C, et al.
BMC Med. 2023;21(1):174.
Leggi
Piona C, Marigliano M, Roncarà C, et al.
Diabetes Technol Ther. Pub. online 8 May 2023.
Leggi
Simmons D, Immanuel J, Hague WM, et al.
N Engl J Med. Pub. online 5 May 2023.
Leggi
Golla KK, Gupta Y, Goyal A, et al.
Diabetes Technol Ther. Pub. online 27 Apr 2023.
Leggi
Palmiero G, Cesaro A, Galiero R, et al.
Diabetes Res Clin Pract. 2023;110686.
Leggi
Chetboun M, Drumez E, Ballou C, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00082-7.
Leggi
Verrastro O, Panunzi S, Castagneto-Gissey L, et al.
Lancet. 2023;S0140-6736(23)00634-7.
Leggi